ArticleStem cell research & therapy2026
Extracellular vesicles from TNF-α and TGF-β1-treated ADSCs promote tissue-engineered cartilage regeneration by modulating macrophages via the miR-378a-3p/SIRPα axis.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MiR-378a-3p Promotes Macrophage Polarization from M1 to M2 for Cardiac Repair after Infarction Via Trem1.Journal of cardiovascular translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) possess immunomodulatory properties and are concurrently influenced by the local inflammatory microenvironment. Extracellular vesicles (EVs) derived from MSCs (MSCs-EVs) replicate the therapeutic effects of their parent cells while avoiding the limitations of cell therapy. Elucidating the impact of diverse inflammatory factors on the composition and functionality of MSCs-EVs is crucial for their optimal use, though this remains incompletely understood. The aim of this study was to explore the immunomodulatory effects and underlying mechanisms of EVs derived from adipose-derived stem cells (ADSCs) pretreated with TNF-α and TGF-β1 (α-EVs and β-EVs) on macrophages and tissue-engineered cartilage regeneration.
methodsIsolation and identification of EVs from ADSCs cultured in 3D spheres. The effects on chondrocyte and macrophage proliferation, migration, and polarization were evaluated in vitro. In vivo, chondrocytes-laden porous GelMA hydrogel with EVs were implanted into mice to assess chondrocyte regeneration and macrophage infiltration. Small RNA sequencing revealed distinct EVs-miRNA expression profiles, and the target validation confirmed the molecular mechanism.
resultsIn vitro, both α-EVs and β-EVs demonstrated the capacity to modulate macrophage phenotypes. α-EVs more effectively reduced M1 macrophage markers and enhanced M2 polarization. Besides, β-EVs exhibited a stronger inhibitory effect on macrophage proliferation and migration, while also promoting chondrocyte proliferation and extracellular matrix (ECM) formation. In vivo, β-EVs significantly improved ECM deposition and chondrocyte maintenance, while both EVs groups reduced M1 infiltration and increased M2 presence. Small RNA sequencing identified miR-378a-3p upregulation in both α-EVs and β-EVs, targeting Signal-regulatory protein alpha (SIRPα) to modulate the immune status of macrophages.
conclusionsBoth TNF-α and TGF-β1 enhanced the immunomodulatory effects of EVs, with TGF-β1 showing a stronger capacity to promote chondrocyte proliferation and ECM synthesis. The miR-378a-3p/SIRPα axis was identified as a key mechanism underlying the protective effects of both α-EVs and β-EVs. This study provides valuable insights into optimizing EVs-based regenerative strategies to regulate the local inflammatory microenvironment and promote the regeneration of engineered tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.